文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-DOTA-JR11与68Ga-DOTATATE PET/CT在转移性高分化神经内分泌肿瘤中的头对头比较:一项前瞻性研究

Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study.
PubMed 文献 · J Nucl Med · 2019-11-01

结果显示68Ga-DOTA-JR11检测肝转移灶更多且靶本比更高,但骨转移灶检测少于68Ga-DOTATATE,原发灶和淋巴结转移两者相当。

要点

  • 68Ga-DOTA-JR11检测肝转移灶数显著多于68Ga-DOTATATE(552 vs 365,P=0.001)。
  • 68Ga-DOTA-JR11的肝病灶靶本比显著高于68Ga-DOTATATE(7.7±5.4 vs 3.4±2.0,P<0.001)。
  • 68Ga-DOTATATE检测骨转移灶数显著多于68Ga-DOTA-JR11(388 vs 158,P=0.016)。

核心结论

  • 68Ga-DOTA-JR11在检测肝转移方面表现更优,靶本比更高;68Ga-DOTATATE在骨转移检测上可能优于68Ga-DOTA-JR11。
  • 68Ga-DOTA-JR11对SSTR2亲和力低于177Lu-DOTA-JR11,可能限制其作为177Lu-DOTA-JR11诊疗配对诊断药物的作用。

研究设计与样本

  • 患者第一天静脉注射68Ga-DOTATATE(155±52 MBq),第二天注射68Ga-DOTA-JR11(148±52 MBq),注射后40-60分钟在同一扫描仪上行全身PET/CT。

主要发现

  • 68Ga-DOTA-JR11上脾脏、肾皮质、肾上腺、垂体、胃壁、正常肝实质、小肠、胰腺和骨髓的SUVmax显著低于68Ga-DOTATATE(P<0.001)。
  • 68Ga-DOTA-JR11检测到肝病灶552个,68Ga-DOTATATE检测到365个(P=0.001);骨病灶分别为158个和388个(P=0.016)。
  • 肝病灶靶本比在68Ga-DOTA-JR11上为7.7±5.4,在68Ga-DOTATATE上为3.4±2.0(P<0.001)。
  • 基于患者和基于病灶的比较中,原发肿瘤和淋巴结转移两者结果相当。

临床怎么用

  • 对于怀疑肝转移的转移性高分化神经内分泌肿瘤患者,68Ga-DOTA-JR11 PET/CT可能提供更高的肝病灶检出率和靶本比。
  • 评估骨转移时,68Ga-DOTATATE PET/CT可能更敏感,68Ga-DOTA-JR11可能遗漏部分骨病灶。
  • 68Ga-DOTA-JR11作为177Lu-DOTA-JR11诊疗配对的诊断药物时需谨慎,因其SSTR2亲和力较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-DOTA-JR11 is a somatostatin receptor subtype 2-specific antagonist used for PET/CT imaging. The purpose of this study was to compare 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors. Methods: Patients with histologically proven, metastatic or unresectable, well-differentiated neuroendocrine tumors were prospectively recruited to this study. Each patient received an intravenous injection of 68Ga-DOTATATE (155 ± 52 MBq) on the first day and 68Ga-DOTA-JR11 (148 ± 52 MBq) on the second day. Whole-body PET/CT scans were performed at 40-60 min after injection on the same scanner. Physiologic normal-organ uptake, lesion numbers, and lesion uptake were compared. Results: Thirty-one patients were prospectively enrolled in the study. The SUVmax of the spleen, renal cortex, adrenal glands, pituitary glands, stomach wall, normal liver parenchyma, small intestine, pancreas, and bone marrow was significantly lower on 68Ga-DOTA-JR11 than on 68Ga-DOTATATE PET/CT (P < 0.001). 68Ga-DOTA-JR11 detected significantly more liver lesions (552 vs. 365, P = 0.001) but fewer bone lesions (158 vs. 388, P = 0.016) than 68Ga-DOTATATE. The target-to-background ratio of liver lesions was significantly higher on 68Ga-DOTA-JR11 (7.7 ± 5.4 vs. 3.4 ± 2.0, P < 0.001). 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT showed comparable results for primary tumors and lymph node metastases on both patient-based and lesion-based comparisons. Conclusion:68Ga-DOTA-JR11 performs better in detecting liver metastases, with a better tumor-to-background ratio, whereas 68Ga-DOTATATE may outperform 68Ga-DOTA-JR11 in the detection of bone metastases. However, the lower somatostatin receptor subtype 2 affinity of 68Ga-DOTA-JR11 than of 177Lu-DOTA-JR11 may limit its role as a diagnostic pair for the theranostic approach with 177Lu-DOTA-JR11.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhu W, Cheng Y, Wang X, et al. Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study. J Nucl Med. 2019. PMID: 31676731. doi:10.2967/jnumed.119.235093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。